Skip to main content

Table 4 Shows percentage of rhabdoid tumor cell lines (A204, G401) surviving, in early or in late apoptosis after 72 h of treatment with SAHA as a single compound or in combination with 4HPR

From: The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells

Cell line

Control

SAHA 1 μM

SAHA 10 μM

4HPR 1 μM

4HPR 10 μM

SAHA 1 μM

      

4HPR 1 μM

A204

      

% surviving cells

85.1 +/− 2.6

87.5 +/− 0.2

66.7 +/− 0.6

87.8 +/− 1.4

49.1 +/− 1.1

40.2 +/− 0.8

% early apoptosis

4.8 +/− 0.1

4.1 +/− 0.2

8.5 +/− 0.2

6.2 +/− 1.0

7.7 +/− 0.5

6.9 +/− 0.4

% late apoptosis

10.1 +/− 2.5

8.4 +/− 0.3

24.8 +/− 1.5

8.3 +/− 0.7

43.1 +/− 0.7

6.9 +/− 0.4

G401

      

% surviving cells

90.3 +/− 0.8

91.2 +/− 1.5

64.7 +/− 2.9

92.3 +/− 2.2

60.0 +/− 2.2

62.9 +/− 3.2

% early apoptosis

5.2 +/− 0.6

5.1 +/− 0.9

23.6 +/− 0.9

4.1 +/− 1.2

26.9 +/− 0.7

27.3 +/− 1.3

% late apoptosis

4.5 +/− 0.2

3.8 +/− 0.7

11.7 +/− 2.1

3.6 +/− 1.0

13.1 +/− 1.4

9.8 +/− 4.2